Bank of America Initiates Coverage on CeriBell (NASDAQ:CBLL)

Stock analysts at Bank of America initiated coverage on shares of CeriBell (NASDAQ:CBLL) in a note issued to investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $32.00 price target on the stock. Bank of America‘s price objective indicates a potential upside of 15.19% from the company’s current price.

Several other analysts have also commented on CBLL. TD Cowen initiated coverage on CeriBell in a research note on Tuesday. They issued a “buy” rating and a $31.00 price target on the stock. William Blair initiated coverage on CeriBell in a research report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. initiated coverage on CeriBell in a research report on Tuesday. They issued an “overweight” rating and a $32.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $31.00.

CeriBell Trading Up 3.0 %

Shares of CBLL stock opened at $27.78 on Tuesday. CeriBell has a one year low of $23.00 and a one year high of $28.94.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.